<p><strong>Kyntra Bio Inc.</strong> (NASDAQ: KYNB)，前身为 Fibrogen，周二盘前交易中股价波动，因公司公布了 FG-3246 与恩杂鲁胺联合治疗转移性去势耐药前列腺癌的 1b/2 期研究数据。</p>
<p><strong>Astellas Pharma Inc.</strong> (OTC: ALPMF) (OTC: ALPMY) 和 <strong>Pfizer Inc.</strong> (NYSE: PFE) 正在共同以 Xtandi 品牌名商业化恩杂鲁胺。</p>
<h2>前列腺癌数据显示反应率为 21%</h2>
<p>数据显示，在仅接受过一种雄激素受体通路抑制剂（ARPI）治疗后进展的患者中，中位放射学无进展生存期（rPFS）为 10.1 个月。</p>
<p>该研究包括 44 名患者，在整体队列中复合反应率为 21%，在仅接受过一种 ARPI 治疗后进展的患者中为 40%。</p>
<p>此外，研究强调了一种趋势，表明 FG-3180 的肿瘤摄取量越高，达到 PSA50 反应的概率越大。结果在 2026 年美国临床肿瘤学会泌尿系统癌症研讨会上公布。</p>
<p>整体队列中观察到的中位 rPFS 为 7.0 个月。</p>
<p>FG-3246 与恩杂鲁胺的联合治疗显示出与之前 FG-3246 单药治疗 1 期试验相似的安全性特征。使用 G-CSF 预防措施降低了中性粒细胞减少症的风险。</p>
<p>FG-3246 目前正在进行 2 期单药治疗试验，预计在 2026 年下半年公布中期数据。</p>
<h2>分析师观点</h2>
<p><strong>William Blair</strong> 在周二表示：“虽然承认跨试验比较的所有局限性和警告，但我们认为 FG-3246 的联合结果具有启发性，并为即将进行的 2 期单药治疗试验中期分析提供了验证。”</p>
<p>分析师 <strong>Andy Hsieh</strong> 进一步补充道：“我们还强调，预防性生长因子的使用似乎减少了剂量限制性中性粒细胞减少症，这对单药研究也应有利。”</p>
<p>总体而言，William Blair 表示，他们对 FG-3246 项目产生的初步结果感到鼓舞。</p>
<p>鉴于 FG-3246 的早期阶段以及前列腺癌市场的高度竞争，分析师 Hsieh 表示，等待更多数据是明智的。William Blair 重申对 Kyntra 股票的市场表现评级。</p>
<p><strong>KYNB 价格动态：</strong> 根据 Benzinga Pro 的数据，Kyntra Bio 的股价在周二盘前交易中上涨了 0.75%，至 8.110 美元。</p>
<p><em>图片来源于 Shutterstock</em></p>

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Kyntra Bio Inc.（纳斯达克代码：KYNB）宣布了 FG-3246 与恩杂鲁胺联合用于转移性去势抵抗性前列腺癌的 1b/2 期研究的积极数据。研究显示中位放射学无进展生存期为 10.1 个月，综合反应率为 21%。威廉·布莱尔的分析师对结果表示鼓励，但由于市场竞争激烈，建议保持谨慎。Kyntra 的股价在盘前交易中上涨了 0.75%，至 8.110 美元</p>

<p><strong>Kyntra Bio Inc.</strong> (NASDAQ: KYNB), formerly Fibrogen, shares fluctuated in Tuesday’s premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide for treating metastatic castration- resistant prostate cancer.</p>
<div class="lb-trans"><p><strong>Kyntra Bio Inc.</strong> (NASDAQ: KYNB)，前身为 Fibrogen，周二盘前交易中股价波动，因公司公布了 FG-3246 与恩杂鲁胺联合治疗转移性去势耐药前列腺癌的 1b/2 期研究数据。</p>
</div><p><strong>Astellas Pharma Inc.</strong> (OTC: ALPMF) (OTC: ALPMY) and <strong>Pfizer Inc.</strong> (NYSE: PFE) are jointly commercializing enzalutamide under the Xtandi brand name.</p>
<div class="lb-trans"><p><strong>Astellas Pharma Inc.</strong> (OTC: ALPMF) (OTC: ALPMY) 和 <strong>Pfizer Inc.</strong> (NYSE: PFE) 正在共同以 Xtandi 品牌名商业化恩杂鲁胺。</p>
</div><h2>Prostate Cancer Data Shows Response Rate Of 21%</h2>
<div class="lb-trans"><h2>前列腺癌数据显示反应率为 21%</h2>
</div><p>The data presented showed a median radiographic progression-free survival (rPFS) of 10.1 months in patients who had progressed on only one prior androgen receptor pathway inhibitor (ARPI).</p>
<div class="lb-trans"><p>数据显示，在仅接受过一种雄激素受体通路抑制剂（ARPI）治疗后进展的患者中，中位放射学无进展生存期（rPFS）为 10.1 个月。</p>
</div><p>The study included 44 patients, with a composite response rate of 21% in the overall cohort and 40% in patients who had progressed on only one prior ARPI.</p>
<div class="lb-trans"><p>该研究包括 44 名患者，在整体队列中复合反应率为 21%，在仅接受过一种 ARPI 治疗后进展的患者中为 40%。</p>
</div><p>In addition, the study highlighted a trend suggesting that higher tumor uptake of FG-3180 was associated with a greater probability of achieving a PSA50 response. The results were presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.</p>
<div class="lb-trans"><p>此外，研究强调了一种趋势，表明 FG-3180 的肿瘤摄取量越高，达到 PSA50 反应的概率越大。结果在 2026 年美国临床肿瘤学会泌尿系统癌症研讨会上公布。</p>
</div><p>Median rPFS of 7.0 months was observed in the overall cohort.</p>
<div class="lb-trans"><p>整体队列中观察到的中位 rPFS 为 7.0 个月。</p>
</div><p>Combination therapy of FG-3246 and enzalutamide demonstrated a similar safety profile as was observed in the previous Phase 1 monotherapy trial of FG-3246. Neutropenia risk was mitigated with the use of G-CSF prophylaxis.</p>
<div class="lb-trans"><p>FG-3246 与恩杂鲁胺的联合治疗显示出与之前 FG-3246 单药治疗 1 期试验相似的安全性特征。使用 G-CSF 预防措施降低了中性粒细胞减少症的风险。</p>
</div><p>FG-3246 is currently being evaluated in a Phase 2 monotherapy trial with interim data expected in the second half of 2026.</p>
<div class="lb-trans"><p>FG-3246 目前正在进行 2 期单药治疗试验，预计在 2026 年下半年公布中期数据。</p>
</div><h2>Analyst View</h2>
<div class="lb-trans"><h2>分析师观点</h2>
</div><p><strong>William Blair</strong> on Tuesday wrote, “While acknowledging all the limitations and caveats associated with cross-trial comparison, we believe the FG-3246 combination results are provocative and provide validation heading into the Phase II monotherapy trial interim analysis, slated to occur in the second half.”</p>
<div class="lb-trans"><p><strong>William Blair</strong> 在周二表示：“虽然承认跨试验比较的所有局限性和警告，但我们认为 FG-3246 的联合结果具有启发性，并为即将进行的 2 期单药治疗试验中期分析提供了验证。”</p>
</div><p>“We also emphasize that the administration of prophylactic growth factor appears to reduce dose-limiting neutropenia, which should also bode well for the monotherapy study,” analyst <strong>Andy Hsieh</strong> further added.</p>
<div class="lb-trans"><p>分析师 <strong>Andy Hsieh</strong> 进一步补充道：“我们还强调，预防性生长因子的使用似乎减少了剂量限制性中性粒细胞减少症，这对单药研究也应有利。”</p>
</div><p>Overall, William Blair says they are encouraged by initial results generated from the FG-3246 program.</p>
<div class="lb-trans"><p>总体而言，William Blair 表示，他们对 FG-3246 项目产生的初步结果感到鼓舞。</p>
</div><p>Given the early stage of FG-3246, along with the highly competitive prostate cancer market, analyst Hsieh says it is prudent to wait for additional data. William Blair reiterates a Market Perform rating on Kyntra shares.</p>
<div class="lb-trans"><p>鉴于 FG-3246 的早期阶段以及前列腺癌市场的高度竞争，分析师 Hsieh 表示，等待更多数据是明智的。William Blair 重申对 Kyntra 股票的市场表现评级。</p>
</div><p><strong>KYNB Price Action:</strong> Kyntra Bio shares were up 0.75% at $8.110 during premarket trading on Tuesday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>KYNB 价格动态：</strong> 根据 Benzinga Pro 的数据，Kyntra Bio 的股价在周二盘前交易中上涨了 0.75%，至 8.110 美元。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

Kyntra Bio 股票在星期二发生了什么情况？